TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
Study: NCT01121302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: 0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00591201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
Study: NCT03857113

Intervention type: PROCEDURE
Intervention: PSMA-radioguided surgery
Description: PSMA-radioguided surgery
Study: NCT03878121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env145NFL
Description: 10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env145NFL
Description: 10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env150KN
Description: 10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-Env150KN
Description: 10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Description: 500-mcg dose of protein boost vaccine formulated for intramuscular administration.
Study: NCT01979757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Puregraft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centrifugation
Study: NCT03878121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Description: 500-mcg dose of protein boost vaccine formulated for intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Description: 500-mcg dose of protein boost vaccine formulated for intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Description: 500-mcg dose of protein boost vaccine formulated for intramuscular administration.
Study: NCT03249506

Intervention type: DRUG
Intervention: Canagliflozin
Description: Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.

Intervention type: DRUG
Intervention: Empagliflozin
Description: Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)
Description: Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.

Intervention type: DRUG
Intervention: Glucagon-Like Peptide-1 Agonist (GLP-1)
Description: Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.

Intervention type: DRUG
Intervention: Thiazolidinedione (TZD)
Description: Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.

Intervention type: DRUG
Intervention: Insulin
Description: Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Study: NCT02960399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax®
Description: Zostavax® immunization

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax®
Description: Zostavax® immunization
Study: NCT05374044

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic MRI for establishing new mrTRG method
Description: they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
Study: NCT03790332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule, tablet, or suspension administered orally once daily
Study: NCT00927056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Minimally invasive microdiscectomy versus conventional open microdiscectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Minimally invasive microdiscectomy versus conventional open microdiscectomy
Study: NCT03224221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil and platinum
Description: the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil and platinum
Description: the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
Study: NCT01457781

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device
Description: Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo delivered via INOpulse DS Device
Description: Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Description: Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
Study: NCT00312702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falciparum Malaria Protein 11 with AS02A adjuvant
Description: vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falciparum Malaria Protein 11 with AS02A adjuvant
Description: vaccine
Study: NCT03468933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
Description: Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Thoracoscopy
Description: Medical thoracoscopy will be performed as per standard protocols.
Study: NCT03028662

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
Study: NCT00717314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1.5 to 2.0 g daily PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1.5 to 2.0 g daily PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNI (50%)
Description: 50% reduction from BL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNI (≥75%)
Description: ≥75% reduction from BL
Study: NCT01208740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill three times daily
Study: NCT01483937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usual care physical therapy plus SEMD
Description: Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care physical therapy only
Description: Subjects will receive usual care physical therapy from vestibular and balance specialists.
Study: NCT02541825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the stent of diameter of 7mm
Description: 108 patients use the stent of diameter of 7mm in TIPS

Intervention type: DEVICE
Group type: OTHER
Intervention: the stent of diameter of 8mm
Description: 108 patients use the stent of diameter of 8mm in TIPS
Study: NCT02084537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment
Description: Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical necrosectomy
Description: Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
Study: NCT01478542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricover-scheme rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricover-scheme rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimised rituximab-schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimised rituximab-schedule
Study: NCT02041689

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.

Intervention type: BEHAVIORAL
Intervention: Observations
Description: Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.

Intervention type: BEHAVIORAL
Intervention: Guided Activities
Description: This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment.
Study: NCT02628392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a tablets 25mg, 50mg, 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a tablets 25mg, 50mg, 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a tablets 25mg, 50mg, 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: matching DS-8500a tablets and sitagliptin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: matching DS-8500a tablets and sitagliptin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: matching DS-8500a tablets and sitagliptin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: matching DS-8500a tablets and sitagliptin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching DS-8500a tablets and sitagliptin capsules
Study: NCT03764033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Killing (IOK)
Description: Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
Study: NCT02600949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Applied topically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotigalimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic Tumor-Associated Peptide Vaccine Therapy
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic Tumor-Associated Peptide Vaccine Therapy
Description: Given SC
Study: NCT03028662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
Study: NCT03519256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study: NCT01645800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysozyme hydrochloride
Description: LYL 90mg capsule: Three times daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo capsule: Three times daily for 52 weeks.
Study: NCT01773148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arstasis Access System (AXERA)
Description: Placement of the AXERA device in the Femoral Artery.
Study: NCT01323348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~* Measurement of HbA1c in office with immediate feedback~* Measurement of blood pressure with immediate feedback~* Assessment of retinopathy risk with immediate feedback~* Personalized risk assessment reports based on current HbA1c~* Brief assessment of patient understanding of key issues with immediate feedback~* Supplemental diabetes management educational materials (provided at baseline only)~* Feedback to primary care provider~* Email reminder to study participants with email access of individualized risk assessment findings
Study: NCT04304482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73 oral liquid
Description: Liquid oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral liquid
Description: Liquid oral solution
Study: NCT02600949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic Tumor-Associated Peptide Vaccine Therapy
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03108157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratch
Description: Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
Study: NCT00903786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
Study: NCT04045730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
Study: NCT01852058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
Study: NCT05234359

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology Testing
Description: A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample
Description: Stool samples collected for genetic, microbial and viral analysis.
Study: NCT02434289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary protein products
Description: Increased protein intake via dairy products, guided by a dietician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.